No Data
No Data
CG Oncology Amends Key Executive Employment Agreements
H.C. Wainwright Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $75
Pfizer Study Impact on CG Oncology to Be Minimal, Says H.C. Wainwright
Buy Rating for CG Oncology, Inc.: Strong Potential Amid Market Dynamics and Strategic Positioning
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Cuts Target Price to $83
LifeSci Capital Remains a Buy on CG Oncology, Inc. (CGON)